The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects.
To study the effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide. Eighteen healthy male subjects were divided into three groups according to their genotypes: group I, CYP2C9*1/*1 and CYP2C19 extensive metabolizers (EMs); group II, CYP2C9*1/*1...
| Publicado en: | European Journal of Clinical Pharmacology Vol. 66; no. 2; pp. 145 - 152 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Springer Nature
Feb2010
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105292080&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 105292080 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00316970 NP9 jtl: European Journal of Clinical Pharmacology issn: 00316970 maglogo: N pubinfo: dt: Feb2010 vid: 66 iid: 2 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 105292080 2010536082 10.1007/s00228-009-0736-2 NLM19847408 105292080 ppf: 145 ppct: 7 formats: fmt: @attributes: type: P tig: atl: The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects. aug: au: Tan B Zhang Y Chen X Zhao X Li G Zhong D affil: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203 China sug: subj: Genes Physiology Glipizide Pharmacodynamics Polymorphism, Genetic Analysis of Variance China Chromatography Methods Data Analysis Software Funding Source Glipizide Blood Glipizide Pharmacokinetics Glipizide Therapeutic Use Human Patient Care Methods Pharmacy and Pharmacology ab: To study the effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide. Eighteen healthy male subjects were divided into three groups according to their genotypes: group I, CYP2C9*1/*1 and CYP2C19 extensive metabolizers (EMs); group II, CYP2C9*1/*1 and CYP2C19 poor metabolizers (PMs); and group III, CYP2C9*1/*3 and CYP2C19 EMs. After a single dose of a 5-mg glipizide tablet, plasma concentrations of glipizide for a 36-h period were determined. Meanwhile, plasma glucose levels and plasma insulin levels were determined from 0 to 4 h after dosing. The area under the plasma concentration-time curve ( $$ AU{C_{0 - \infty }} $$) was 2.0-fold higher and the oral clearance was 51.1% lower in group III than in group I. The change in fasting insulin level within 1 h ([Delta]AUECinsulin0-1h) in group III was 3.8-fold higher than that in group I. The glipizide parameters in group II exhibited similar tendencies to those in group III. These results suggest that CYP2C9 polymorphism significantly influences the pharmacokinetics and pharmacodynamics of glipizide, which needs to be considered in clinical practice. CYP2C19 polymorphism exhibits a tendency to influence the effects of glipizide, to a certain extent similarly to CYP2C9 polymorphism. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|